-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Lung cancer remains the leading cause of cancer-related deaths
Lung cancer remains the leading cause of cancer-related deaths
HER2 gene amplification and overexpression are present in many tumor types, including NSCLC
A total of 12,946 NSCLC patients were included in this study with analyzable EGFR and HER2 NGS data
A total of 12,946 NSCLC patients were included in this study with analyzable EGFR and HER2 NGS data
321 patients (2.
1551 patients (12%) had EGFR mutations, of which 68% were women, with a median age of 68 years
Among the samples with EGFR mutations, 24 cases (1.
The median treatment time for patients with EGFR mutation and HER2 amplification was 846 days (N=12), while the median treatment time for patients with EGFR mutation and HER2 amplification was 286 days (N=826), HR=2.
The median treatment time for patients with EGFR mutation and HER2 amplification was 846 days (N=12), while the median treatment time for patients with EGFR mutation and HER2 amplification was 286 days (N=826), HR=2.
Prognosis
Similarly, the median treatment time for EGFR mutation and HER2 ECD mutation patients was 462 days (N=8), while the median treatment time for EGFR mutation and HER2 wild-type patients was 287 days (N=891), HR=1.
Similarly, the median treatment time for EGFR mutation and HER2 ECD mutation patients was 462 days (N=8), while the median treatment time for EGFR mutation and HER2 wild-type patients was 287 days (N=891), HR=1.
In summary, studies have shown that there are very few HER2 changes in NSCLC patients with EGFR mutations
Original source:
Misako Nagasaka, Vijendra Singh, Yasmine Baca, et al.
Misako Nagasaka, Vijendra Singh, Yasmine Baca, et al.
The Effects of HER2 alterations in EGFR mutant non-small cell lung cancer.
Clinical Lung Cancer.
DOI: https://doi.
org/10.
1016/j.
cllc.
2021.
08.
012
Leave a message here
